Amphivena Therapeutics Inc., of South San Francisco, appointed Curtis L. Ruegg president and CEO and to its board.
Caraway Therapeutics Inc., of Cambridge, Mass., appointed Martin D. Williams CEO and Cristina Csimma chair of its board.
Cardiol Therapeutics Inc., of Oakville, Ontario, appointed Colin Stott to its board.
Excision Biotherapeutics Inc., of Oakland, Calif., appointed William H. Carson to its board.
Hemostemix Inc., of Calgary, Alberta, appointed Bryson Goodwin to its board.
Homology Medicines Inc., of Bedford, Mass., appointed Gabriel M. Cohn chief medical officer.